Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma

PURPOSE: Evaluate the efficacy and safety of triple therapeutic method (Hepatic Aarterial Infusion Chemotherapy—HAIC, lenvatinib and sequential ablation) in the treatment for Advanced Hepatocellular carcinoma (Ad‐HCC). MATERIALS AND METHODS: From November 2018 to June 2021, data from 150 consecutive Ad‐HCC patients were collected. All patients received HAIC combined with lenvatinib (H‐L group, n = 97) or HAIC combined with lenvatinib and sequential ablation (H‐L‐A group, n = 53). Complications, overall survival (OS), progression‐free survival (PFS) and intrahepatic progression‐free survival (IPFS) were compared between both groups. RESULTS: No significant differences of baseline characteristics were found between groups. The time of median follow‐up was 17.8 months (range, 6.8, 37.6 months). In comparison to the H‐L group, the H‐L‐A group patients showed significantly longer median OS (>30 months vs 13.6 months, respectively; p = 0.010), PFS (12.8 vs. 5.6 months, respectively; p < 0.001), and IPFS (14.6 vs. 6.8 months, respectively; p = 0.002). According to the results from uni‐ and multivariable analyses, we considered α‐fetoprotein and treatment modality as two survival independent prognostic factors. No significant change of the complication incidences was observed between H‐L group and H‐L‐A group (12.4% vs. 11.3%, p = 0.890). CONCLUSION: Compared to HAIC combined with lenvatinib only, HAIC combined with lenvatinib and sequential ablation was safer and more effective, improving survival outcomes of Ad‐HCC patients. A prospective study will be designed validate the retrospective results.